Oklahoma House Bill HB2817

Oklahoma 2025 Regular Session

• Introduced: 2/3/25
• Refer: 2/4/25

Caption

Health care; creating the Oklahoma Rebate Pass-Through and Pharmacy Benefits Manager Meaningful Transparency Act of 2025; definitions; requirements; effective date.

Impact

If enacted, HB2817 would necessitate significant changes in the operations of PBMs as well as the relationships they maintain with health insurers and pharmacies. By requiring these entities to disclose rebate information and ensuring that a substantial portion of rebates are reflected in lower costs at the register, the bill aims to empower consumers and potentially lower overall prescription drug expenses for Oklahoma residents. Further, the bill includes provisions to penalize noncompliance with these requirements, placing responsibility on PBMs to adhere to the new regulations.

Summary

House Bill 2817, known as the Oklahoma Rebate Pass-Through and Pharmacy Benefits Manager Meaningful Transparency Act of 2025, seeks to enhance transparency in prescription drug pricing by mandating that pharmacy benefits managers (PBMs) disclose specific information regarding drug rebates. The bill stipulates that at least 85% of rebate amounts obtained related to a prescription drug must be passed on to the individual at the point of sale, aiming to reduce out-of-pocket costs for patients. This measure reflects ongoing concerns about the high costs of medications and the need for greater consumer awareness of pricing structures within the pharmaceutical supply chain.

Contention

One notable point of contention surrounding this bill is the balance between transparency and confidentiality of commercial agreements. Critics may argue that while increased transparency is necessary to safeguard consumer interests, mandatory disclosure of rebates could deter pharmaceutical companies from participating in rebate programs entirely, thus affecting drug pricing and availability. Additionally, the bill’s provisions might be viewed as an undue burden on PBMs, raising concerns about operational feasibility and the implications of significantly altering rebate structures in the industry.